Skip to main navigation Skip to search Skip to main content

Clinical Radiobiology for Radiation Oncology

  • Peter Sminia*
  • , Olivier Guipaud
  • , Kristina Viktorsson
  • , Vidhula Ahire
  • , Sarah Baatout
  • , Tom Boterberg
  • , Jana Cizkova
  • , Marek Dostál
  • , Cristian Fernandez-Palomo
  • , Alzbeta Filipova
  • , Agnès François
  • , Mallia Geiger
  • , Alistairl Hunter
  • , Hussam Jassim
  • , Nina Frederike Jeppesen Edin
  • , Karl Jordan
  • , Irena Koniarová
  • , Vinodh Kumar Selvaraj
  • , Aidan D. Meade
  • , Fabien Milliat
  • Alegría Montoro, Constantinus Politis, Diana Savu, Alexandra Sémont, Ales Tichy, Vlastimil Válek, Guillaume Vogin
*Corresponding author for this work
  • Amsterdam UMC
  • Autorité de sûreté nucléaire et de radioprotection
  • Karolinska Institutet
  • J. Michael Bishop Institute of Cancer Research
  • Chengdu Anticancer Bioscience, Ltd, Chengdu, China
  • Belgian Nuclear Research Center
  • Ghent University
  • KU Leuven
  • University of Defence in Brno
  • Masaryk University
  • University of Bern
  • University of Cape Town
  • General Najaf Hospital
  • University Al-Hilla College
  • University of Oslo
  • Technological University Dublin
  • Státní Ústav Radiacní ochrany
  • Thanjavur Medical College
  • Hospital Universitario La Fe
  • Horia Hulubei National Institute of Physics and Nuclear Engineering
  • University of Luxembourg

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

222 Downloads (Pure)

Abstract

This chapter is focused on radiobiological aspects at the molecular, cellular, and tissue level which are relevant for the clinical use of ionizing radiation (IR) in cancer therapy. For radiation oncology, it is critical to find a balance, i.e., the therapeutic window, between the probability of tumor control and the probability of side effects caused by radiation injury to the healthy tissues and organs. An overview is given about modern precision radiotherapy (RT) techniques, which allow optimal sparing of healthy tissues. Biological factors determining the width of the therapeutic window are explained. The role of the six typical radiobiological phenomena determining the response of both malignant and normal tissues in the clinic, the 6R’s, which are Reoxygenation, Redistribution, Repopulation, Repair, Radiosensitivity, and Reactivation of the immune system, is discussed. Information is provided on tumor characteristics, for example, tumor type, growth kinetics, hypoxia, aberrant molecular signaling pathways, cancer stem cells and their impact on the response to RT. The role of the tumor microenvironment and microbiota is described and the effects of radiation on the immune system including the abscopal effect phenomenon are outlined. A summary is given on tumor diagnosis, response prediction via biomarkers, genetics, and radiomics, and ways to selectively enhance the RT response in tumors. Furthermore, we describe acute and late normal tissue reactions following exposure to radiation: cellular aspects, tissue kinetics, latency periods, permanent or transient injury, and histopathology. Details are also given on the differential effect on tumor and late responding healthy tissues following fractionated and low dose rate irradiation as well as the effect of whole-body exposure.
Original languageEnglish
Title of host publicationRadiobiology Textbook
PublisherSpringer International Publishing
Pages237-309
ISBN (Electronic)9783031188107
ISBN (Print)9783031188091
DOIs
Publication statusPublished - 1 Jan 2023

Publication series

NameRadiobiology Textbook

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Clinical Radiobiology for Radiation Oncology'. Together they form a unique fingerprint.

Cite this